JEIL PHARMACEUTICAL CO.,LTD

271980· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩10,170+4.95%

2026-08-04

Financials

Valuation Metrics

JEIL PHARMACEUTICAL CO.,LTD's Market Cap is ₩1495B. At end of 2025 it was ₩2228B. Ranked #992 of 2,436 in KR market (top 41%), #504 of 787 on KOSPI (top 64%), #117 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	149.55B KRW	KR#992/2,436 Sec#117/234
Revenue	534.52B KRW	KR#583/2,436 Sec#30/234
Net Income	31.60B KRW	KR#492/2,436 Sec#33/234
Total Assets	515.14B KRW	KR#732/2,436 Sec#43/234
Net Assets	257.45B KRW	KR#780/2,436 Sec#53/234
Employees	983	KR#259/2,436 Sec#20/234
Value
P/E	4.73x	KR#255/2,436 Sec#9/234
P/B	0.58x	KR#950/2,436 Sec#44/234
P/S	0.28x	KR#555/2,436 Sec#10/234
EV/EBITDA	12.35x	KR#736/2,436 Sec#39/234
FCF Yield	-9.18%	KR—/2,436 Sec—/234
Profitability
ROE	12.27%	KR#361/2,436 Sec#23/234
ROA	6.13%	KR#515/2,436 Sec#39/234
Op. Margin	2.89%	KR#1,240/2,436 Sec#94/234
Revenue Growth	-20.07%	KR#2,068/2,436 Sec#187/234
Earnings Growth	-11.11%	KR#991/2,436 Sec#65/234
Financial Health
Debt Ratio	100.09%	KR#324/2,436 Sec#40/234
Total Debt	94.78B KRW	KR#735/2,436 Sec#46/234
FCF	-13.72B KRW	KR#1,806/2,436 Sec#163/234
Cash	53.47B KRW	KR#721/2,436 Sec#43/234
Current Ratio	1.35x	KR#1,430/2,436 Sec#151/234
Net Debt/EBITDA	2.67x	KR#937/2,436 Sec#69/234
Dividend
Div. Growth	0.00%	KR—/2,436 Sec—/234
Performance
1Y Return	-26.52%	KR#1,480/2,436 Sec#128/234
1M Return	-0.20%	KR#902/2,436 Sec#80/234
From 52W High	-47.28%	KR#1,070/2,436 Sec#88/234
1Y MDD	-46.92%	KR#787/2,436 Sec#67/234
Trading
Volume	18,566 shares	KR#1,882/2,436 Sec#187/234
Foreign Own.	2.08%	KR—/2,436 Sec—/234
Per Share
EPS	1,391 KRW	KR#499/2,436 Sec#36/234
BPS	14,503 KRW	KR#682/2,436 Sec#46/234

Company Info

CEO 성석제, 한상철 (공동대표)

Employees 983

Founded 2017

HQ 서울특별시 서초구, KR

Website www.jeilpharm.co.kr

동사는 2017년 제일파마홀딩스의 전문의약품사업부문이 인적분할되어 설립, 유가증권시장에 재상장했으며 2020년 온코닉테라퓨틱스를 자회사로 두고 있음. 완제 의약품 제조 및 판매를 주사업으로 전문의약품 시장에서 종합병원, 의원, 약국 유통채널을 통해 사업을 추진하고 있음. 지속 성장 위해 내부 연구개발 및 외부 기술 연계를 통한 개방형 혁신과 의료환경 변화에 대응하는 전략적 기반을 강화하고 있음. 제일약품는 2017년에 설립되었으며 서울특별시 서초구에 본사를 두고 있습니다.